WHAT'S NEW

  • 12 Oct 2015 3:03 PM | Anonymous

    Researchers at UAMS published an article in Nature Genetics about the genomic landscape of JMML.

    For more information about the study, please click here.

  • 12 Oct 2015 2:56 PM | Anonymous
    A coalition of leukemia researchers led by scientists from the University of California, San Francisco has discovered surprising genetic diversity in JMML.

    For more information and a link to the article, please click here.


  • 08 Oct 2015 2:48 PM | Anonymous

    Scientists at The Mount Sinai Hospital engineered stem cells in order to better understand JMML.

    For more information and to read the article, please click here.

  • 02 Oct 2015 2:37 PM | Anonymous

    Dr. Elliot Stieglitz from the University of California, San Francisco, received Alex's Lemonade Stand Foundation's (ALSF) Young Investigator Grant for his research on DNA mutations in children with JMML.


    For the full article, please click here

  • 23 Jul 2015 10:12 AM | Anonymous


    Source: Childrens Hospital Los Angeles


    Researchers in the Division of Hematology, Oncology and Blood & Marrow

    Transplantation at Children's Hospital Los Angeles have shown greatly 

    improved outcomes in using stem cell transplantation to treat patients with

    a serious..but very rare form of chronic blood cancer called juvenile

    myelomonocytic leukemia (JMML).

    Allogeneic hematopoietic stem cell transplantation (HSCT) involves the transplantation of stem cells from a donor, which may be derived from bone marrow, peripheral blood or umbilical cord blood. The recipient's immune system is usually destroyed with radiation or chemotherapy before the transplantation. It is the only reported cure for JMML; however best outcomes of the therapy have shown only that half of patients can be cured from their disease. According to the researchers, there is currently no standard conditioning regimen for children with JMML undergoing HSCT.

    The CHLA study, led by Hisham Abdel-Azim, MD, looked at children with JMML who underwent HSCT at Children's Hospital Los Angeles. All of the patients were alive and in clinical remission.

    "The lack of transplant-related mortality in the group of children we studied at the Children's Center for Cancer and Blood Diseases at CHLA suggests that BUMEL (Intravenous Busulfan and Melphalan) may represent a successful HSCT high-dose chemotherapy regimen," said Abdel-Azim. "It is also possible that administering conventional dose chemotherapy, before HSCT, to patients with more progressive disease may have contributed to the improved outcomes."

    He added that a follow up clinical trial is warranted to confirm these promising findings, which are published in the July 23, 2015, issue of the journal Blood.

    Story Source:

    The above post is reprinted from materials provided by Childrens Hospital Los AngelesNote: Materials may be edited for content and length.

    Journal Reference:

    1. Q. Zhao, K. M. Mahadeo, N. Kapoor, H. Abdel-Azim. Improved outcomes associated with hematopoietic stem cell transplantation for patients with juvenile myelomonocytic leukemiaBlood, 2015; 126 (4): 561 DOI: 10.1182/blood-2015-05-644161


  • 13 Jul 2015 10:32 AM | Anonymous

    Source: Badische Zeitung

    Dr. Christian Flotho of Freiburg, Germany received the Eleonore and Fritz Hodeige Foundation prize for his advances in JMML research.

    The full article (in German) can be read here.

  • 13 Jul 2015 10:24 AM | Anonymous

    WBTV North Carolina reports on Jake Leatherman, a 4-year-old from Hickory, who is battling JMML.

    See full story here.

  • 22 May 2015 2:43 AM | Anonymous
    Congratulations to Chelsea Jenkins, a Ph.D. student, who was recently awarded $31,388 by Friends of Doernbecher for her proposal to develop novel treatments for children with Juvenile Myelomonocytic Leukemia (JMML). Friends of Doernbecher recently donated $175,000 to the Friends Grant program, which supports Doernbecher Children’s Hospital (DCH) faculty and staff with funding to pursue research or develop projects and programs at the hospital.


    Doernbecher cares for the vast majority of children in Oregon with leukemia, which combined with the excellent research environment of the Knight Cancer Institute makes this an ideal place to develop and implement novel therapeutic strategies to improve outcomes for children with JMML.

    For more information, click here.



This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode
standard for trustworthy health
 
information:  verify here.



Copyright (c) 2016 The JMML Foundation
Powered by Wild Apricot Membership Software